Climb Bio Inc (CLYM) SEC Filings & Earnings Calls

Phase 2 and Phase 3 trials still ongoing; regulatory feedback pending for global Phase 3; early-stage data may not translate to patients.

“NAVIGATE-2 Phase 2 trial enrolling, initial data expected H1 2027; global Phase 3 expected to initiate in 2027 pending regulatory feedback”

Clinical trial risk; Phase 2 data expected in 1H 2027.

“NAVIGATE-2, a Phase 2 study in IgAN, enrolling with initial data anticipated in 1H 2027.” · word for word

No revenue, net loss, and reliance on financing for cash runway

“Clinical stage biotech with no approved products; cash burn from R&D and G&A”

No approved products or revenue

“We currently have no source of product revenue and may never become profitable.” · word for word

Need for additional capital

“We anticipate that it will need to raise substantial financing in the future to fund its operations.”

Clinical development risk

“Nonclinical and clinical development involves a lengthy, complex and expensive process with an uncertain outcome.” · word for word

Material weaknesses in internal controls

“We have identified material weaknesses in our internal control over financial reporting; if we are unable to remediate these material weaknesses ... we may not be able to accurately or timely report our financial condition or results of operations.” · word for word

Litigation risk

“On December 31, 2025, the Company filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, relating to a dispute concerning potential milestone payments owed under the Asset Purchase Agreement.” · word for word

Potential dilution from up to $100M ATM equity offering; prior $22.35M facility terminated with no shares sold.

“Company may offer and sell shares of Common Stock having an aggregate offering price of up to $100.0 million” · word for word

Early-stage clinical data; small sample size; further cohorts and longer follow-up needed

“15 patients enrolled; median follow-up 38 weeks (250mg) and 12 weeks (500mg); 1000mg cohort enrollment ongoing”

No material risks identified; routine governance filing

Early-stage clinical development risk; no revenue or profitability

“Company is pre-revenue with significant R&D expenses and accumulated deficit.”

No product revenue; reliance on future financing

“We currently have no source of product revenue and may never become profitable.” · word for word

Material weakness in internal controls

“We have identified material weaknesses in our internal control over financial reporting.” · word for word

Single-source supplier dependency

“We rely and expect to continue to rely on single-source suppliers and manufacturers to supply us with certain critical materials.”

Litigation risk with Alumis/Acelyrin

“On December 31, 2025, the Company filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, relating to a dispute concerning potential milestone payments.” · word for word

Clinical-stage company with no approved products; reliance on successful trial outcomes and regulatory approvals.

“Company is clinical-stage; all programs in Phase 1 or 2; no revenue from product sales.”

Cash runway depends on operating plan; updated guidance pending after private placement.

“Company expects cash to fund operations into 2028 excluding private placement; updated cash runway guidance to be provided later.”

Dilution risk from issuance of ~11.6M shares (including pre-funded warrants).

“9,481,000 shares + 2,106,000 pre-funded warrants”

Dilution from equity compensation

“As of March 31, 2026, we had outstanding 47,768,543 shares of common stock and prefunded warrants to purchase an aggregate of 20,440,000 shares of common stock.” · word for word

Concentration of ownership by RA Capital

“Entities affiliated with RA Capital beneficially own 33.0% of our common stock as of March 31, 2026.”

Loss of key finance executive may create temporary operational gap, but CFO assumes role, mitigating risk.

“Departure of SVP Finance; CFO appointed as principal accounting officer.”

Clinical-stage biotech with no approved products; high R&D spend and reliance on pipeline success.

“R&D expenses $46.7M in FY2025; no revenue; cash runway into 2028 but dependent on clinical trial outcomes.”

Clinical trial failure risk

“Nonclinical and clinical development involves a lengthy, complex, and expensive process, which is uncertain and may not predict final outcomes.” · word for word

Capital need risk

“If we are unable to access capital when needed and on acceptable terms, we may be forced to delay, reduce, or discontinue our product candidate development programs.” · word for word

Regulatory approval risk

“Our future success is dependent on the regulatory approval and commercialization of our product candidates.” · word for word

Competition risk

“We face significant competition in an environment of rapid technological change.” · word for word

Clinical trial risk; data may not meet endpoints.

“Initial data expected in H2 2026; uncertainty in outcomes.”

Litigation risk: dispute over milestone payment could result in financial liability or impact on drug development.

“The Complaint seeks a declaratory judgment that the Company’s budoprutug drug candidate is not a “Product” under the APA and the Company does not owe a milestone payment sought by Alumis in connection with its development of budoprutug.” · word for word

Shareholder dilution risk from issuance of pre-funded warrants and exchange agreement.

“Item 3.02 Unregistered Sale of Equity Securities; Pre-Funded Warrant form filed as Exhibit 4.1.” · word for word

Clinical-stage company with no approved products or revenue

“No revenue reported; company is clinical-stage with multiple trials ongoing”

Dependence on clinical trial outcomes

“Multiple clinical milestones expected in 2026; trial failures could impact stock”

Pre-revenue biotech with ongoing losses

“We have incurred significant losses since our inception and anticipate that we will incur substantial losses for the foreseeable future and may never achieve or maintain profitability.” · word for word

Need for future financing

“The Company anticipates that it will need to raise substantial financing in the future to fund its operations.” · word for word

Material weakness in internal controls

“We have identified material weaknesses in our internal control over financial reporting.” · word for word